152 related articles for article (PubMed ID: 16139826)
1. Circulating biomarkers of cognitive decline and dementia.
Solfrizzi V; D'Introno A; Colacicco AM; Capurso C; Todarello O; Pellicani V; Capurso SA; Pietrarossa G; Santamato V; Capurso A; Panza F
Clin Chim Acta; 2006 Feb; 364(1-2):91-112. PubMed ID: 16139826
[TBL] [Abstract][Full Text] [Related]
2. Lipid metabolism in cognitive decline and dementia.
Panza F; D'Introno A; Colacicco AM; Capurso C; Pichichero G; Capurso SA; Capurso A; Solfrizzi V
Brain Res Rev; 2006 Aug; 51(2):275-92. PubMed ID: 16410024
[TBL] [Abstract][Full Text] [Related]
3. Plasma biomarkers for mild cognitive impairment and Alzheimer's disease.
Song F; Poljak A; Smythe GA; Sachdev P
Brain Res Rev; 2009 Oct; 61(2):69-80. PubMed ID: 19464319
[TBL] [Abstract][Full Text] [Related]
4. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
6. Plasma lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild cognitive impairment.
Mamo JC; Jian L; James AP; Flicker L; Esselmann H; Wiltfang J
Ann Clin Biochem; 2008 Jul; 45(Pt 4):395-403. PubMed ID: 18583625
[TBL] [Abstract][Full Text] [Related]
7. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
[TBL] [Abstract][Full Text] [Related]
8. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease.
Frisardi V; Solfrizzi V; Seripa D; Capurso C; Santamato A; Sancarlo D; Vendemiale G; Pilotto A; Panza F
Ageing Res Rev; 2010 Oct; 9(4):399-417. PubMed ID: 20444434
[TBL] [Abstract][Full Text] [Related]
9. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
Gurol ME; Irizarry MC; Smith EE; Raju S; Diaz-Arrastia R; Bottiglieri T; Rosand J; Growdon JH; Greenberg SM
Neurology; 2006 Jan; 66(1):23-9. PubMed ID: 16401840
[TBL] [Abstract][Full Text] [Related]
10. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
Irizarry MC; Gurol ME; Raju S; Diaz-Arrastia R; Locascio JJ; Tennis M; Hyman BT; Growdon JH; Greenberg SM; Bottiglieri T
Neurology; 2005 Nov; 65(9):1402-8. PubMed ID: 16275827
[TBL] [Abstract][Full Text] [Related]
11. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
12. Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?
Borroni B; Di Luca M; Padovani A
Eur J Pharmacol; 2006 Sep; 545(1):73-80. PubMed ID: 16831417
[TBL] [Abstract][Full Text] [Related]
13. Plasma biomarkers of Alzheimer's disease.
Kawarabayashi T; Shoji M
Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
[TBL] [Abstract][Full Text] [Related]
14. Cognitive frailty: Predementia syndrome and vascular risk factors.
Panza F; D'Introno A; Colacicco AM; Capurso C; Parigi AD; Capurso SA; Caselli RJ; Pilotto A; Scafato E; Capurso A; Solfrizzi V
Neurobiol Aging; 2006 Jul; 27(7):933-40. PubMed ID: 16023766
[TBL] [Abstract][Full Text] [Related]
15. Plasma beta amyloid and cytokine profile in women with Alzheimer's disease.
Baranowska-Bik A; Bik W; Wolinska-Witort E; Martynska L; Chmielowska M; Barcikowska M; Baranowska B
Neuro Endocrinol Lett; 2008 Feb; 29(1):75-9. PubMed ID: 18283248
[TBL] [Abstract][Full Text] [Related]
16. Decreased levels of serum nitric oxide in different forms of dementia.
Corzo L; Zas R; Rodríguez S; Fernández-Novoa L; Cacabelos R
Neurosci Lett; 2007 Jun; 420(3):263-7. PubMed ID: 17556102
[TBL] [Abstract][Full Text] [Related]
17. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
19. Total serum cholesterol levels and Alzheimer's dementia in patients with Down syndrome.
Prasher VP; Airuehia E; Patel A; Haque MS
Int J Geriatr Psychiatry; 2008 Sep; 23(9):937-42. PubMed ID: 18395888
[TBL] [Abstract][Full Text] [Related]
20. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
